The present invention relates to a crystal form of an imidazolinone derivative. The present invention further relates to a crystal form of a substituted imidazolinone derivative and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor. Specifically, the present invention relates to crystal forms I-VI of the compound as represented by formula (A) and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor.
The present invention relates to a crystal form of an imidazolinone derivative. The present invention further relates to a crystal form of a substituted imidazolinone derivative and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor. Specifically, the present invention relates to crystal forms I-VI of the compound as represented by formula (A) and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor.
The present invention relates to a heterocyclic compound represented by general formula (I), or a stereoisomer, deuterated product, pharmaceutically acceptable salt, solvate, prodrug, metabolite or co-crystal thereof, and also relates to a pharmaceutical composition thereof and a use thereof in a drug for the treatment of MRGPRX4-dependent disorders.
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
3.
PHARMACEUTICAL PREPARATION OF IMIDAZOLINONE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present invention relates to a pharmaceutical preparation of an imidazolinone compound and a preparation method therefor. In particular, the present invention relates to a pharmaceutical formulation of a compound represented by formula I.
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
5.
PYRROLE FUSED RING DERIVATIVE AND PHARMACEUTICAL USE THEREOF
The present invention relates to a pyrrole fused ring derivative or a stereoisomer thereof, a pharmaceutical composition thereof, and the pharmaceutical use thereof; and specifically relates to a pyrrole fused ring derivative as shown in general formula (I), or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a co-crystal thereof, a pharmaceutical composition comprising same, and the use of the compound or composition of the present application in the preparation of a drug for treating cancer. The compound of the present invention has therapeutic effects on Polθ-mediated cancers or tumors, and also has a good selectivity and low side effects.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Provided are a crystal of a substituted piperazine derivative and a preparation method therefor. Specifically, provided are crystal forms A-I of a compound represented by formula (1) and a preparation method therefor.
Provided in the present invention is the use of bilobalide in the preparation of a drug for preventing or treating diabetes and diabetic complications.
The present application relates to a combination of a piperazine compound and a PD-1 inhibitor antibody or a PD-L1 inhibitor antibody and use thereof in treating tumors.
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
C07D 473/02 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6
The present invention relates to an indolone derivative and a use thereof. The indolone derivative can enhance degradation of a target protein and can be used for preparing an antitumor drug.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Disclosed is a method for purifying cannabinoid compounds that enables cannabinoid compounds to be obtained more economically and with a better purification effect.
C07C 37/68 - SeparationPurificationStabilisationUse of additives
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
C07C 37/88 - Use of additives, e.g. for stabilisation
14.
USE OF IMIDAZOLINONE DERIVATIVE IN COMBINATION WITH RADIOTHERAPY IN TREATMENT OF TUMORS
The present invention provides use of a compound represented by general formula (I) in combination with radiotherapy in a medicament for treating cancer.
A pyrrolidine derivative and an application thereof in medicine, specifically relating to the pyrrolidine derivative represented by general formula (I-0) or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or co-crystal thereof, a pharmaceutical composition containing same, and a use of the compound or composition in the preparation of a drug for autoimmune diseases.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/94 - [b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
Tetrahydrocannabinol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
Tetrahydrocannabinol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
18.
IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF
The present application relates to imidazolidinone derivatives and medical use thereof, and in particular relates to pyrimidine derivatives represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or co-crystals thereof, a pharmaceutical composition comprising the same, and use of the compound or pharmaceutical composition according to the present application in the manufacture of a medicament for treatment of cancer.
The present application relates to imidazolidinone derivatives and medical use thereof, and in particular relates to pyrimidine derivatives represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or co-crystals thereof, a pharmaceutical composition comprising the same, and use of the compound or pharmaceutical composition according to the present application in the manufacture of a medicament for treatment of cancer.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A selective PARP1 inhibitor and an application thereof. Provided are a compound represented by general formula (I-A), and a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof. Also provided are a pharmaceutical composition comprising the compound or the stereoisomer thereof, and an application of the compound and the pharmaceutical composition in preparation of anti-tumor drugs.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A selective PARP1 inhibitor and an application thereof. Provided are a compound represented by general formula (I-A), and a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof. Also provided are a pharmaceutical composition comprising the compound or the stereoisomer thereof, and an application of the compound and the pharmaceutical composition in preparation of anti-tumor drugs.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
The present invention relates to a crystal form of an imidazolinone derivative. The present invention further relates to a crystal form of a substituted imidazolinone derivative and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor. Specifically, the present invention relates to crystal forms I-VI of the compound as represented by formula (A) and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor.
The present invention relates to a crystal form of an imidazolinone derivative. The present invention further relates to a crystal form of a substituted imidazolinone derivative and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor. Specifically, the present invention relates to crystal forms I-VI of the compound as represented by formula (A) and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof in the preparation of a DNA-PK inhibitor.
Provided are a preparation process for an imidazolinone derivative or a stereoisomer thereof, and an intermediate thereof. The preparation process involves simple operations, has high reaction yield, achieves high product purity, and is suitable for industrialized production. Also provided is a preparation process for the intermediate.
Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07C 69/94 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
C07C 49/825 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
A pharmaceutical composition, containing bilobalide or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt or eutectic thereof, and cannabidiol or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt or eutectic thereof. The composition is used to prevent and/or treat a non-sedation related disease or disorder.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description.
Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description.
A crystal form of substituted purine derivatives and pharmaceutical compositions thereof, preparation methods, and uses for preparing a DNA-PK inhibitor are related to. Specifically, a crystal form of a compound represented by formula (A), pharmaceutical compositions thereof, preparation methods, and uses for preparing a DNA-PK inhibitor are related to.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention relates to a purine derivative and use thereof in medicine, and in particular to a pyrimidine derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, prodrug, deuteride, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of preparation of a DNA-PK inhibitor, wherein the substituents in general formula (I) are defined in the same way as in the specification
The present invention relates to a purine derivative and use thereof in medicine, and in particular to a pyrimidine derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, prodrug, deuteride, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of preparation of a DNA-PK inhibitor, wherein the substituents in general formula (I) are defined in the same way as in the specification
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
An amide derivative and the pharmaceutical use thereof, in particular, the present invention relates to an amide derivative of formula (I) or a pharmaceutically acceptable salt thereof or all stereoisomers, tautomers and deuterated compounds thereof, and a pharmaceutical composition comprising the above-mentioned compounds. The above-mentioned compounds or composition may be used as an NLRP3 inhibitor, and the definition of each substituent in formula (I) is the same as that in the description.
C07D 307/38 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 333/04 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom
C07C 311/14 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 13/00 - Drugs for disorders of the urinary system
Provided are an amide derivative of formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated products thereof, and a pharmaceutical composition comprising the compound. The compound or composition can be used as an NLRP3 inhibitor. The definition of each substituent in formula (I) is the same as that in the description.
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
Provided are an amide derivative and an application thereof in medicine, in particular, an amide derivative as represented by formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated products thereof, and a pharmaceutical composition comprising the compound above. The compound or composition may be used as an NLRP3 inhibitor.
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/00 - Drugs for disorders of the urinary system
A61P 25/00 - Drugs for disorders of the nervous system
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
The present application relates to a deuterated compound of compound A or a pharmaceutically acceptable salt or stereoisomer thereof, wherein one or more hydrogens of the compound A are replaced by deuterium. The compound is used to treat diseases associated with the central nervous system.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61P 37/00 - Drugs for immunological or allergic disorders
40.
PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE-TYPE COMPOUND AND CANNABIDIOL AND APPLICATION THEREOF IN MEDICINE
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Disclosed are a quinazoline derivative of formula (I), a pharmaceutical composition containing the derivative and the use thereof in medicine, in particular the use as an SOS1 inhibitor and the use in the preparation of a medicament for the treatment or prevention of diseases associated with SOS1.
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Disclosed is use of ginkgo terpene lactone in preparing a drug for preventing and/or treating Guillain-Barré-Strohl syndrome. Ginkgo terpene lactone has certain effects on relieving the condition of EAN mice, and the use of a combination of different ginkgo terpene lactone monomer compounds shows a certain synergistic effect. Ginkgo terpene lactone can be used clinically to prevent and/or treat the symptoms of Guillain-Barré-Strohl syndrome, and no adverse reactions have been observed. The means of obtaining the medical raw materials is common, preparation costs are lower, the costs of patient treatment are low, and safety is high.
Disclosed are a pyridine derivative and the use thereof in medicine. The pyridine derivative has a good binding effect with LANCL2 protein, and has a significant efficacy on ulcerative colitis.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Disclosed in the present application is a novel piperazine-2,3-dione derivative or a pharmaceutically acceptable salt or stereoisomer thereof, a pharmaceutical composition thereof, and an application thereof in the preparation of a KRAS/G12C inhibitor; the compound can improve the curative effect whilst reducing toxic side effects.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/499 - Spiro-condensed pyrazines or piperazines
Disclosed is a method for preparing cannabinoid compounds and prodrugs thereof, which method has a good purification effect and is suitable for industrial production.
Disclosed is a method for purifying cannabinoid compounds that enables cannabinoid compounds to be obtained more economically and with a better purification effect.
C07D 311/74 - Benzo [b] pyrans, hydrogenated in the carbocyclic ring
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
49.
PYRIDAZINONE DERIVATIVES AND USE THEREOF IN MEDICINE
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Disclosed are a pharmaceutical composition comprising a bilobalide component and a pharmaceutically acceptable carrier or excipient, and a pharmaceutical preparation of a bilobalide component comprising a bilobalide component, a pharmaceutically acceptable carrier or excipient, and water, and the use of the pharmaceutical composition and the pharmaceutical preparation.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention relates to a cannabinoid derivative and the medical use thereof. Specifically, the present invention relates to a cannabinoid derivative as represented by general formula (I) or a stereoisomer, a solvate, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof, wherein the definition of each substituent in general formula (I) is the same as that in the description.
C07F 9/12 - Esters of phosphoric acids with hydroxyaryl compounds
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
The present application relates to an imidazolinone derivative and the use thereof in medicine, and specifically relates to a pyrimidine derivative as represented by general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or co-crystal thereof, a pharmaceutical composition containing same and the use of the compound or the composition of the present application in the preparation of drugs for treating cancers.
The present application relates to an imidazolinone derivative and the use thereof in medicine, and specifically relates to a pyrimidine derivative as represented by general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or co-crystal thereof, a pharmaceutical composition containing same and the use of the compound or the composition of the present application in the preparation of drugs for treating cancers.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention relates to a tetrahydrocannabinol derivative and the medical use thereof. Specifically, the present invention relates to a pyrimidine derivative as shown in general formula (I) or a stereoisomer, a solvate, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof, wherein the definition of each substituent in general formula (I) is the same as the definition in the description.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Provided are a cannabidiol derivative and the medical use thereof. Specifically, the present invention relates to a pyrimidine derivative as shown in general formula (I) or a stereoisomer, a solvate, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof, wherein the definition of each substituent in general formula (I) is the same as the definition in the description.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
57.
CANNABIDIOL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
Provided are a cannabidiol derivative and the medical use thereof. Specifically, the present invention relates to a pyrimidine derivative as shown in general formula (I) or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a co-crystal thereof, wherein the definition of each substituent in general formula (I) is the same as the definition in the description.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention relates to a triazole derivative and medical use thereof. Specifically, the present invention relates to a pyrimidine derivative represented by the general formula (I), or a stereoisomer thereof, a solvate thereof, a prodrug thereof, a deutero compound thereof, a metabolite thereof, a pharmaceutically acceptable salt or an eutectic thereof, a pharmaceutical composition comprising same, and use of the compound or the composition in the field of preparing DNA-PK inhibitors, wherein the definitions of the substituents in the general formula (I) are the same as the definitions in the description.
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A class of furan derivatives and an application thereof in medicine; specifically, the furan derivatives relate to pyrimidine derivatives represented by general formula (I'), or stereoisomers, solvates, prodrugs, metabolites, deuterated products, pharmaceutically acceptable salts or eutectic crystals thereof, a pharmaceutical composition comprising same, and a use of the compounds or composition in the preparation of a DNA-PK inhibitor, wherein the definition of each substituent in general formula (I') is the same as the definition thereof in the specification.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to a purine derivative and the medical use thereof; in particular, the present invention relates to a purine derivative as shown by general formula (I), or a stereoisomer, solvate, metabolite, prodrug, deuterated compound, pharmaceutically acceptable salt or eutectic compound thereof, a pharmaceutical composition containing same and the use of the compound and the composition in the field of preparing a DNA-PK inhibitor, wherein the definition of each of the substituents in general formula (I) is the same as the definition in the description.
A use of one or more of a Ginkgo biloba terpene lactone compound or a pharmaceutically acceptable salt, ester, hydrate, solvate, or isomer thereof, or any crystal form, racemate, or metabolite of same, or a mixture of same as an active ingredient in the preparation of drugs for the prevention and/or treatment of tremors, and healthcare products. The Ginkgo biloba terpene lactone compound and composition can both significantly improve the disease condition of essential tremor model mice; the ameliorating effect of a Ginkgo biloba terpene lactone B and bilobalide composition and a ginkgolide A, ginkgolide B, and ginkgolide C composition on the essential tremor model mice is close to that of the positive control drug propranolol hydrochloride. The disease condition of patients with essential tremors and patients with vascular tremors is significantly improved, and there have been no adverse reactions in clinical observations.
An amide derivative and an application thereof in medicine, specifically relating to the amide derivative represented by general formula (I) or a stereoisomer, solvate, a metabolic product, a deuterated product, a prodrug, a pharmaceutically acceptable salt or a co-crystal thereof, and a pharmaceutical composition containing same, and use of the compound or composition in the preparation of an NLRP3 inhibitor.
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/00 - Drugs for disorders of the urinary system
A61P 25/00 - Drugs for disorders of the nervous system
The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
64.
USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRÉ-STROHL SYNDROME
A use of ginkgo terpene lactone in preparing a drug for preventing and/or treating Guillain-Barré-Strohl syndrome. Ginkgo terpene lactone has certain effects on relieving the condition of EAN mice, and the use of a combination of different ginkgo terpene lactone monomer compounds shows a certain synergistic effect. Ginkgo terpene lactone can be used clinically to prevent and/or treat the symptoms of Guillain-Barré-Strohl syndrome, and no adverse reactions have been observed. The means of of obtaining the medical raw materials is common, preparation costs are lower, the costs of patient treatment are low, and safety is high.
A dropping pill comprising ginkgo terpene lactones as active components and a preparation method therefor. The dropping pill comprises ginkgo terpene lactones, a matrix, a filler having a rigid molecular structure, and/or a filler having a loose and porous surface.
A use of one or more of a ginkgo biloba terpene lactone compound or a pharmaceutically acceptable salt, ester, hydrate, solvate, or isomer thereof, or any crystal form, racemate, or metabolite of same, or a mixture of same as an active ingredient in the preparation of drugs for the prevention and/or treatment of tremors, and healthcare products. The problem of the lack of drugs for the prevention or treatment of tremors in the current pharmaceutical field is solved. The ginkgo biloba terpene lactone compound and composition can both significantly improve the disease condition of essential tremor model mice; the ameliorating effect of a ginkgo biloba terpene lactone B and bilobalide composition and a ginkgolide A, ginkgolide B, and ginkgolide C composition on the essential tremor model mice is close to that of the positive control drug propranolol hydrochloride. The disease condition of patients with essential tremors and patients with vascular tremors is significantly improved, and there have been no adverse reactions in clinical observations.
A pharmaceutical composition containing ginkgolide B and an ADP receptor antagonist, a preparation method thereof and use thereof in preparation of antiplatelet drugs, wherein the ADP receptor antagonist is clopidogrel, prasugrel, ticagrelor and/or ticlopidine.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
68.
Pharmaceutical composition containing Ginkgolide B and Xa factor inhibitor, preparation method thereof and use thereof
A pharmaceutical composition containing ginkgolide B and an Xa factor inhibitor xaban, a preparation method and use of the pharmaceutical composition, wherein the xaban is selected from Rivaroxaban, Apixaban, Edoxaban, Razaxaban and Otamixaban.
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Pharmaceutical composition containing Ginkgolide B and blood platelet prostaglandin cyclooxygenase inhibitor and method for preparation thereof and use thereof
Provided is a pharmaceutical composition containing ginkgolide B and the blood platelet prostaglandin cyclooxygenase inhibitor aspirin, a method for preparation of the pharmaceutical composition and a use thereof. When used together, ginkgolide B and aspirin have a synergistic effect in resisting platelet aggregation.
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A pharmaceutical composition containing ginkgolide B and an ADP receptor antagonist, a preparation method thereof and use thereof in preparation of antiplatelet drugs, wherein the ADP receptor antagonist is clopidogrel, prasugrel, ticagrelor and/or ticlopidine.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A pharmaceutical composition containing ginkgolide B and an X a factor inhibitor xaban, a preparation method and use of the pharmaceutical composition, wherein the xaban is selected from Rivaroxaban, Apixaban, Edoxaban, Razaxaban and Otamixaban.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A pharmaceutical composition containing ginkgolide B and an Xa factor inhibitor xaban, a preparation method and use of the pharmaceutical composition, wherein the xaban is selected from Rivaroxaban, Apixaban, Edoxaban, Razaxaban and Otamixaban.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE B AND BLOOD PLATELET PROSTAGLANDIN CYCLOOXYGENASE INHIBITOR, AND METHOD FOR PREPARATION THEREOF AND USE THEREOF
Provided are a pharmaceutical composition containing ginkgolide B and the blood platelet prostaglandin cyclooxygenase inhibitor aspirin, a method for preparation of said pharmaceutical composition, and a use thereof. When used together, ginkgolide B and aspirin have a synergistic effect in resisting platelet aggregation.
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
A method for extracting and separating ginkgolides. The ginkgolides obtained through steps of extraction on a ginkgo leaf, further extraction, column chromatography, crystallization, and crystal mixing comprise 25.0% to 50.0% of bilobalide (C15H18O8), 20.0% to 45.0% of ginkgolide A (C20H24O9), 10.0% to 30.0% of ginkgolide B (C20H24O10), and 5.0% to 15.0% of ginkgolide C (C20H24O11). The total quantity of the bilobalide, the ginkgolide A, the ginkgolide B, and the ginkgolide C is over 95%.
C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
patents
